This knowledge could pave the way for targeted therapies, including EGFR inhibitors, STAT3 blockade or immune checkpoint modulation, tailored to the particular immune landscape of APS-1 [80,81,82,83,84]. The gene discussed is STAT3; the disease is autoimmune polyendocrine syndrome type 1.